November 05, 2025

Get In Touch

Using Depression Screening Tools In Patients With Kidney Failure

Depression Screening in Kidney Failure Patients

Depression Screening in Kidney Failure Patients

Washington, DC - A recent analysis examines research on the use of depression screening tools in patients with kidney failure. The results appear in an upcoming issue of CJASN.

People with kidney failure experience depression at rates higher than the general population. Medicare requires routine depression screening for patients with kidney failure, but no clear guidance on which methods to use.

Karli Kondo, PhD (VA Portland Health Care System and Oregon Health & Science University) and her colleagues conducted a review to identify depression screening tools that are appropriate for patients with kidney failure, and to better understand the impact of depression screening in this population.

The investigators identified 16 relevant studies that evaluated the performance characteristics of depression assessment tools for patients with kidney failure. A tool called the Beck Depression Inventory II (BDI-II) was by far the most extensively studied, with 9 studies examining its performance. Other tools included:

  • Cognitive Depression Index (CDI)
  • Center for Epidemiologic Studies - Depression Scale (CES-D)
  • Hospital Anxiety and Depression Scale - Depressive Subscale (HADS-D)
  • Geriatric Depression Scale-15 (GDS-15)
  • Hamilton Depression Rating Scale (Ham-D)
  • Patient Health Questionnaire 2 (PHQ-2)
  • PHQ-9
  • Others

"Our hope was that we'd find evidence that pointed to an optimal screening tool. This was optimistic of course, for if there was one that had strong evidence, it would already be in use," said Dr. Kondo. "We also hoped that we'd find some evidence to support the use of the tools that are common in practice. And we didn't. The PHQ-2 and -9 are widely used in medical settings and are free. The CES-D is another that is commonly used. We found only one study each of the PHQ-9 and the CES-D, and no studies of the PHQ-2."

Dr. Kondo noted that many of the studies were conducted overseas, and it's unclear how applicable they are to patients in the United States. Many of the studies were small, and among the studies examining the same tools, there wasn't much agreement in the cutoff values chosen to define depression and its severity.

An accompanying editorial notes that there are multiple practical considerations to take into account when considering the best screening tool to identify depression in patients with kidney failure on dialysis.

A Patient Voice also accompanies the study and provides the perspective of a veteran with kidney disease who was diagnosed with depression through the PHQ-9 tool.

For more information, visit the CJASN website.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!